Hyperparathyroidism associated with hypophosphatemic osteomalacia: Case report and review of the literature;Hiperparatireoidismo associado à osteomalacia hipofosfatêmica do adulto: Relato de caso e revisão da literatura

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 1, 2006, Pages 150-155

  Moreira, Rodrigo O ^a,c,d   Leal, Christianne T S ^c   Lacativa, Paulo Gustavo S ^c   Figueiredo, João Guilherme ^b   Lima, Maurício B ^b   Farias, Maria Lucia F ^c  

^a Servico de Endocrinologia   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d NONE   (Brazil)

Author keywords

Hyperparathyroidism; Hypophosphatemia; Oncogenic osteomalacia; Osteomalacia

Indexed keywords

EID: 33646736297     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302006000100021     Document Type: Article

References (15)

1. Firth RG, Grant CS, Riggs BL. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Am J Med 1985;78:669-73.
2. Younis E, Jarrah N, Sroujieh AS, Hadidy AA, Ajlouni K. Tertiary hyperparathyroidism after high-dose phosphate therapy in adult-onset hypophosphatemic osteomalacia. Endoc Prac 2001;7:375-8.
3. Reid IR, Teitelbaum SL, Dusso A, Whyte M. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Effects of successful tumor resection on mineral homeostasis. Am J Med 1987;83:350-4.
4. Clunie GPR, Fox PE, Stamp TCB. Four cases of acquired hypophosphatemic ("oncogenic") osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology 2000;39:1415-21.
5. Verge CF, Lam A, Simprsom JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Eng J Med 1991;325:1843-8.
6. Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 1992;75:1514-8.
7. Coffey RJ, Lee TC, Canary JJ. The surgical treatment of primary hyperparathyroidism: a 20-year experience. Ann Surg 1977;185:518-23.
8. Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature and report of two new cases. Am J Med 1984;77-501-12.
9. rd ed. Philadelphia: Lippincott-Raven, 1996. p.319-25.
10. Almaden Y, Canalejo A, Hernandez A, Garcia-Navarro S, Torres A, Rodriguez M. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996;11:970-6.
11. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-40.
12. Carpenter TO. Oncogenic Osteomalacia - A complex dance of factors. N Eng J Med 2003;348:1705-8.
13. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5.
14. Nguyen BD, Wang EA. Indium-111 pentreotide scintigraphy of mesenchymal tumor with osteomalacia oncogenica. Clin Nucl Med 1999;24:130-1.
15. Seufert J, Ebert K, Muller J, Euler J, Hendrich C, Werner E, et al. Octreotide therapy for tumor-induced osteomalacia. N Eng J Med 2001;345:1883-8.